The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
ConclusionOnce-weekly semaglutide may represent a cost-effective add-on therapy alternative to sitagliptin for type 2 diabetes patients inadequately controlled on metformin in China.
Source: Health Economics Review - Category: International Medicine & Public Health Source Type: research
More News: China Health | Diabetes | Diabetes Type 2 | Economics | Endocrinology | Fortamet | International Medicine & Public Health | Janumet | Januvia | Metformin